Method for increasing intradermal retention amount of polypeptide in cosmetic product, and Anti-aging cosmetic product
By forming a viscous reverse micelle structure in cosmetics to transport peptides, the problem of peptides' inability to penetrate the stratum corneum is solved, achieving efficient retention of peptides in the skin and enhancing anti-aging effects, while avoiding skin damage and providing safety.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- GUANGDONG MARUBI BIOLOGICAL TECH CO LTD
- Filing Date
- 2025-11-25
- Publication Date
- 2026-06-18
AI Technical Summary
Peptides in existing cosmetics have difficulty penetrating the natural lipid barrier of the stratum corneum, resulting in limited intradermal retention and poor anti-aging effects. Furthermore, the use of oil-soluble surfactants in existing methods may damage the skin and has low biocompatibility.
Aqueous mixtures are prepared by mixing peptides with water, and oil-phase mixtures are prepared by mixing peptides with phospholipids, oils and antioxidants to form viscous reverse micelle structures. This allows peptides to be transported below the stratum corneum. The viscous reverse micelle structure is used as a transporter for peptides to increase intradermal retention.
It effectively increases the amount of peptides retained in the skin, enhances the anti-aging effects of anti-aging cosmetics, avoids damage to the skin, and improves biosafety.
Smart Images
Figure CN2025137528_18062026_PF_FP_ABST
Abstract
Description
Methods to increase the intradermal retention of peptides in cosmetics, anti-aging cosmetics
[0001] Cross-reference to related applications
[0002] This disclosure claims priority to Chinese Patent Application No. 2024118240268, filed on December 11, 2024, entitled "Method for increasing the intradermal retention of polypeptides in cosmetics, anti-aging cosmetics", the entire contents of which are incorporated herein by reference. Technical Field
[0003] This disclosure relates to the field of cosmetics, and more specifically, to a method for increasing the intradermal retention of peptides in cosmetics and anti-aging cosmetics. Background Technology
[0004] As we age and are exposed to environmental damage, our skin begins to show signs of aging. Consumers often tend to use cosmetics with anti-aging properties to combat premature skin aging, but in reality, cosmetics work through their active ingredients.
[0005] However, most effective anti-aging ingredients on the market have difficulty penetrating the natural lipid barrier formed by the stratum corneum. These anti-aging ingredients can only exert their effects better when they penetrate into the epidermis or dermis and accumulate in that skin layer.
[0006] For example, peptides have excellent anti-aging effects, but they have difficulty penetrating the natural lipid barrier formed by the stratum corneum, and their retention in the skin is limited, which means that their anti-aging effects are not truly effective.
[0007] Known existing technologies, such as Chinese patent CN110339081B, typically use oil-soluble surfactants as solubilizers to dissolve peptides in oily solvents and increase their intradermal retention. However, this method requires the introduction of oil-soluble surfactants, which can easily damage the skin and has low biocompatibility. Summary of the Invention
[0008] The purpose of this disclosure is to provide a method for increasing the intradermal retention of polypeptides in cosmetics and an anti-aging cosmetic.
[0009] In a first aspect, this disclosure provides a method for increasing the intradermal retention of peptides in cosmetics, comprising:
[0010] An aqueous mixture was prepared by mixing the peptide with water.
[0011] An oil-phase mixture was prepared by mixing phospholipids, oils, and antioxidants.
[0012] When the aqueous phase mixture is added dropwise to the oil phase mixture, a viscous reverse micelle structure is formed.
[0013] In the above technical solution, an aqueous mixture of peptides and water is added dropwise to an oil-phase mixture of phospholipids, oils, and antioxidants, forming a viscous reverse micelle structure. This viscous reverse micelle structure can act as a transporter for peptides, carrying water-soluble peptides below the natural lipid barrier formed by the stratum corneum; simultaneously, this viscous reverse micelle structure can increase the retention of peptides in the skin; thus, it can effectively enhance the anti-aging efficacy of existing anti-aging cosmetics.
[0014] In other embodiments of this disclosure, the above-described method of mixing the polypeptide with water to obtain an aqueous mixture includes:
[0015] In the aqueous mixture, the peptides are mixed with water at a mass percentage ratio of (0.01%–70%):(30%–99.99%).
[0016] In other embodiments of this disclosure, an oil phase mixture is prepared by mixing phospholipids, oils, and antioxidants, comprising:
[0017] Phospholipids, oils and antioxidants are mixed in a ratio of (20%–50%):(45%–78%):(1.0%–2.0%) by weight percentage.
[0018] In other embodiments of this disclosure, adding the aqueous phase mixture dropwise to the oil phase mixture includes:
[0019] Add the homogeneous aqueous phase mixture dropwise to the oil phase mixture and stir.
[0020] In other embodiments of this disclosure, adding the aqueous phase mixture dropwise to the oil phase mixture includes:
[0021] Add 1%-3% of the aqueous phase mixture dropwise to the 97%-99% oil phase mixture by mass percentage, and stir.
[0022] In other embodiments of this disclosure, the oil includes at least one of isopropyl palmitate, isopropyl myristate, or isopropyl laurate.
[0023] In other embodiments of this disclosure, the antioxidant includes tocopherol acetate.
[0024] In other embodiments of this disclosure, the polypeptide includes at least one of conotoxin, snake venom-like peptide, or acetyl hexapeptide-8.
[0025] In other embodiments of this disclosure, the phospholipids include lecithin, and the purity of the lecithin is 90% to 100%.
[0026] Secondly, this disclosure provides an anti-aging cosmetic, which includes polypeptide raw materials;
[0027] The polypeptide raw materials form a viscous reverse micelle structure.
[0028] In other embodiments of this disclosure, the polypeptide raw materials, by mass percentage, comprise: 45%-78% oils; 20%-50% phospholipids; 1.0%-2.0% antioxidants; 1.0%-3% water; and 0.0001%-1.0% polypeptides.
[0029] In other embodiments of this disclosure, the oil includes at least one of isopropyl palmitate, isopropyl myristate, or isopropyl laurate.
[0030] In other embodiments of this disclosure, the antioxidant includes tocopherol acetate.
[0031] In other embodiments of this disclosure, the polypeptide includes at least one of conotoxin, snake venom-like peptide, or acetyl hexapeptide-8.
[0032] In other embodiments of this disclosure, the phospholipids include lecithin, and the purity of the lecithin is 90% to 100%. Attached Figure Description
[0033] To more clearly illustrate the technical solutions of the embodiments of this disclosure, the accompanying drawings used in the embodiments will be briefly described below. It should be understood that the following drawings only show some embodiments of this disclosure and should not be regarded as a limitation of the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.
[0034] Figure 1 is a transmission electron microscope image of conopeptide transported by the reverse micelle transporter prepared in Example 2 of this disclosure.
[0035] Figure 2 is a transmission electron microscope image of the reverse micelle transporter carrying snake venom peptides prepared in Example 7 of this disclosure.
[0036] Figure 3 is a transmission electron microscope image of acetyl hexapeptide-8 transported by the reverse micelle transporter prepared in Example 12 of this disclosure. Detailed Implementation
[0037] To make the objectives, technical solutions, and advantages of the embodiments of this disclosure clearer, the technical solutions in the embodiments of this disclosure will be clearly and completely described below. Obviously, the described embodiments are some embodiments of this disclosure, but not all embodiments.
[0038] Therefore, the following detailed description of embodiments of this disclosure is not intended to limit the scope of the claimed disclosure, but merely to illustrate selected embodiments of the disclosure. All other embodiments obtained by those skilled in the art based on the embodiments of this disclosure without inventive effort are within the scope of protection of this disclosure.
[0039] Research has shown that phospholipids can form reverse micelle structures to encapsulate water-soluble active ingredients, acting as carriers and thus enhancing their stability. Further studies have revealed that this reverse micelle structure can simultaneously transport peptides and increase their retention in the skin.
[0040] This disclosure provides a method for increasing the intradermal retention of peptides in cosmetics, comprising:
[0041] An aqueous mixture was prepared by mixing the peptide with water.
[0042] An oil-phase mixture was prepared by mixing phospholipids, oils, and antioxidants.
[0043] When the aqueous phase mixture is added dropwise to the oil phase mixture, a viscous reverse micelle structure is formed.
[0044] In the above technical solution, an aqueous mixture prepared by mixing peptides and water is added dropwise to an oil-phase mixture prepared by mixing phospholipids and oils, forming a viscous reverse micelle structure. This viscous reverse micelle structure can act as a transport carrier for peptides, delivering water-soluble peptides below the natural lipid barrier formed by the stratum corneum; simultaneously, this viscous reverse micelle structure can increase the retention of peptides in the skin; thus, it can effectively enhance the true anti-aging efficacy of existing anti-aging cosmetics.
[0045] Further optionally, in some embodiments of this disclosure, the viscosity of the above-described viscous reverse micelle structure is 25000 Pa·s-35000 Pa·s.
[0046] In some embodiments of this disclosure, the viscosity test method for the above-described viscous reverse micelle structure is as follows:
[0047] Based on the estimated sample viscosity, select a suitable rotor and install it on the rotational viscometer shaft. Connect the rotor to the instrument drive system, ensuring a tight, secure connection without any shaking. Carefully and slowly pour the temperature-controlled sample into the measuring cylinder until the sample is submerged in the rotor's graduation mark, avoiding the introduction of air bubbles. If air bubbles are present, allow them to settle briefly to allow them to escape, or gently pop any surface bubbles with a fine needle. Turn on the viscometer, set the rotation speed, and wait for the reading to stabilize. Record the displayed viscosity value and repeat the measurement three times.
[0048] For example, in some embodiments of this disclosure, the viscosity of the viscous reverse micelle structure described above is 25000 Pa·s, 26000 Pa·s, 27000 Pa·s, 28000 Pa·s, 29000 Pa·s, 30000 Pa·s, 31000 Pa·s, 32000 Pa·s, 33000 Pa·s, 34000 Pa·s, 35000 Pa·s, or a range between any two of the aforementioned values.
[0049] Furthermore, in some embodiments of this disclosure, the polypeptide is mixed with water to prepare an aqueous mixture, including:
[0050] The polypeptide was mixed with water at a mass percentage ratio of (0.01%–70%):(30%–99.99%).
[0051] Exemplary, in some embodiments of this disclosure, the above-described method of mixing the polypeptide with water to obtain an aqueous mixture includes:
[0052] In the aqueous mixture, the peptides are mixed with water in a mass percentage ratio of 0.01:99.99, 1:99, 5:95, 10:90, 15:85, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, or any two of the aforementioned values.
[0053] In the above technical solution, the peptide and water are mixed in a ratio of (0.01% to 70%):(30% to 99.99%) by mass percentage; this is beneficial for obtaining a viscous reverse micelle structure with moderate viscosity, and for increasing the amount of peptide retained in the skin.
[0054] Furthermore, in some embodiments of this disclosure, an oil-phase mixture is prepared by mixing phospholipids, oils, and antioxidants, comprising:
[0055] Phospholipids, oils and antioxidants are mixed in a ratio of (20%–50%):(45%–78%):(1.0%–2.0%) by weight percentage.
[0056] Exemplarily, in some embodiments of this disclosure, phospholipids are mixed with oils to obtain an oil phase mixture, including:
[0057] By weight percentage, phospholipids and oils are mixed in the following proportions: 20%: 45%: 1.0%; 21%: 49%: 1.1%; 22%: 50%: 1.2%; 25%: 55%: 1.3%; 28%: 58%: 1.4%; 30%: 60%: 1.5%; 32%: 62%: 1.6%; 35%: 65%: 1.7%; 38%: 69%: 1.8%; 40%: 70%: 1.9%; 45%: 75%: 2.0%; 48.5%: 78%: 1.0% or any two of the aforementioned values.
[0058] In the above technical solution, phospholipids, oils and antioxidants are mixed in the following proportions by mass: (20%-50%):(45%-78%):(1.0%-2.0%). This is beneficial for obtaining a viscous reverse micelle structure with appropriate viscosity, which is beneficial for increasing the retention of peptides in the skin.
[0059] Furthermore, in some embodiments of this disclosure, the aqueous phase mixture is added dropwise to the oil phase mixture, including:
[0060] Add the homogeneous aqueous phase mixture dropwise to the oil phase mixture and stir.
[0061] Exemplarily, optionally, in some embodiments of this disclosure, adding the aqueous phase mixture dropwise to the oil phase mixture includes:
[0062] Add the peptide to water and stir to mix evenly to obtain a homogeneous aqueous mixture;
[0063] Phospholipids, oils, and antioxidants are mixed, heated, and stirred until homogeneous to obtain a homogeneous oil phase mixture.
[0064] Then, the well-stirred aqueous phase mixture is added dropwise to the well-stirred oil phase mixture, and stirred at room temperature until a viscous reverse micelle is formed.
[0065] Furthermore, in some embodiments of this disclosure, the aqueous phase mixture is added dropwise to the oil phase mixture, including:
[0066] Add 1%-3% of the aqueous phase mixture dropwise to the 97%-99% oil phase mixture by mass percentage, and stir.
[0067] Exemplarily, in some embodiments of this disclosure, adding an aqueous phase mixture dropwise to an oil phase mixture includes:
[0068] By weight percentage, add dropwise to an oil phase mixture containing 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3%, or any two of the aforementioned values, and stir.
[0069] In the above technical solution, by mass percentage, 1%-3% of the aqueous phase mixture is added dropwise to 97%-99% of the oil phase mixture and stirred. Within the above range, it is beneficial to obtain a viscous reverse micelle structure with moderate viscosity, which is beneficial to increase the retention of peptides in the skin.
[0070] Further, in some embodiments of this disclosure, the oil includes at least one of isopropyl palmitate, isopropyl myristate, isopropyl laurate, or isopropyl acetate. Exemplarily, in some embodiments of this disclosure, the oil is selected from any one of isopropyl palmitate, isopropyl myristate, isopropyl laurate, or isopropyl acetate; or in some embodiments of this disclosure, the oil includes a mixture of isopropyl palmitate and isopropyl myristate; or in some embodiments of this disclosure, the oil includes a mixture of isopropyl laurate and isopropyl acetate; or in some embodiments of this disclosure, the oil includes a mixture of isopropyl palmitate, isopropyl myristate, isopropyl laurate, and isopropyl acetate; the raw materials in each of the above mixtures can be mixed in any proportion.
[0071] Furthermore, in some embodiments of this disclosure, the antioxidant includes at least one of butylated hydroxyanisole, butylated hydroxytoluene, tocopheryl acetate, propyl gallate, or tert-butylhydroquinone.
[0072] For example, in some embodiments of this disclosure, the antioxidant is selected from any one of butylated hydroxyanisole, butylated hydroxytoluene, tocopheryl acetate, propyl gallate, or tert-butylhydroquinone; or in some embodiments of this disclosure, the antioxidant includes a mixture of butylated hydroxyanisole and butylated hydroxytoluene; or in some embodiments of this disclosure, the antioxidant includes a mixture of butylated hydroxytoluene and tocopheryl acetate; or in some embodiments of this disclosure, the antioxidant includes a mixture of butylated hydroxytoluene, tocopheryl acetate, propyl gallate, and tert-butylhydroquinone; the raw materials in each of the above mixtures can be mixed in any proportion.
[0073] Furthermore, in some embodiments of this disclosure, the polypeptide includes at least one of conostipeptide, snake venom-like peptide, or acetyl hexapeptide-8.
[0074] For example, in some embodiments of this disclosure, the polypeptide is selected from any one of conotoxin, snake venom-like peptide, or acetyl hexapeptide-8; or in some embodiments of this disclosure, the polypeptide is selected from a mixture of conotoxin and snake venom-like peptide; or in some embodiments of this disclosure, the polypeptide is selected from a mixture of conotoxin, snake venom-like peptide, and acetyl hexapeptide-8; the raw materials in each of the above mixtures can be mixed in any proportion.
[0075] Furthermore, in some embodiments of this disclosure, the phospholipids include lecithin, and the purity of the lecithin is 90% to 100%.
[0076] For example, in some embodiments of this disclosure, the purity of lecithin is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a range between any two of the aforementioned values.
[0077] Secondly, some embodiments of this disclosure provide an anti-aging cosmetic product, which includes a polypeptide raw material; the polypeptide raw material forms a viscous reverse micelle structure.
[0078] Furthermore, in some embodiments of this disclosure, the polypeptide raw materials, by mass percentage, include: 45%-78% oils; 20%-50% phospholipids; 1.0%-2.0% antioxidants; and 1.0%-3.0% water; 0.0001%-1.0% polypeptides.
[0079] For example, in some embodiments of this disclosure, the polypeptide raw material includes, by mass percentage: 45%, 47%, 49.5%, 50%, 50.5%, 51%, 51.5%, 52%, 52.5%, 53%, 53.5%, 55%, 56%, 58%, 60%, 62%, 65%, 68%, 70%, 72%, 75%, 78%, or oils within any two of the aforementioned values;
[0080] Phospholipids of 20%, 22%, 24%, 26%, 28%, 30%, 35%, 40%, 45%, 48%, 50%, or any two of the aforementioned values;
[0081] Antioxidants in the range of 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, or any two of the aforementioned values;
[0082] 1.0%, 1.1%, 1.2%, 1.3%, 1.5%, 1.8%, 2%, 2.1%, 2.2%, 2.3%, 2.5%, 2.6%, 2.8%, 3%, or water within any two of the aforementioned values; and
[0083] A polypeptide of 0.0001%, 0.0005%, 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.15%, 0.5%, 0.8%, 1.0%, or any range between any two of the aforementioned values.
[0084] In the above technical solution, the polypeptide raw materials, by mass percentage, include: 45%-78% oil; 20%-50% phospholipids; 1.0%-2.0% antioxidants; and 1.0%-3.0% water; 0.0001%-1.0% polypeptides. Within this range, polypeptide anti-aging cosmetics with a longer retention time in the skin can be obtained, which is beneficial to improving the true anti-aging effect of anti-aging cosmetics.
[0085] Furthermore, in some embodiments of this disclosure, the oil includes at least one of isopropyl palmitate, isopropyl myristate, isopropyl laurate, or isopropyl acetate.
[0086] Furthermore, in some embodiments of this disclosure, the antioxidant includes at least one of butylated hydroxyanisole, butylated hydroxytoluene, tocopheryl acetate, propyl gallate, or tert-butylhydroquinone.
[0087] Furthermore, in some embodiments of this disclosure, the polypeptide includes at least one of conostipeptide, snake venom-like peptide, or acetyl hexapeptide-8.
[0088] Furthermore, in some embodiments of this disclosure, the phospholipids include lecithin, and the purity of the lecithin is 90% to 100%.
[0089] For example, in some embodiments of this disclosure, the purity of the lecithin is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a range between any two of the aforementioned values.
[0090] In other optional embodiments of this disclosure, the anti-aging cosmetics described above may also include other cosmetic bases commonly used in the art, and the aforementioned polypeptide raw materials are compounded with the cosmetic base to form anti-aging cosmetics.
[0091] Further optionally, in some embodiments of this disclosure, the amount of the aforementioned polypeptide raw material added in the anti-aging cosmetic is 0.0001% to 1.0% by mass percentage; exemplaryly, in some embodiments of this disclosure, the amount of the aforementioned polypeptide raw material added in the anti-aging cosmetic is 0.0001%, 0.0005%, 0.001%, 0.002%, 0.003%, 0.01%, 0.02%, 0.03%, 0.05%, 0.1%, 0.2%, 0.5%, 0.8%, 1.0%, or a range between any two of the aforementioned values.
[0092] Further, alternatively, in some embodiments of this disclosure, the cosmetic matrix described above may include moisturizers, emulsifiers, thickeners, etc., commonly used in the art.
[0093] The features and performance of this disclosure will be further described in detail below with reference to embodiments:
[0094] Examples and Comparative Examples
[0095] A polypeptide raw material is provided, and the formulation of each embodiment is shown in Tables 1-3.
[0096] Table 1
[0097] Table 2
[0098] Table 3
[0099] Preparation process:
[0100] Weigh each raw material according to the component proportions of each embodiment or comparative example in Tables 1-3 above:
[0101] Each embodiment was prepared according to the following preparation method:
[0102] S1. Mix phospholipids, oils and antioxidants, heat and stir to form a homogeneous oil phase mixture;
[0103] S2. Mix and stir the various raw materials in the aqueous phase until a homogeneous aqueous mixture is formed;
[0104] S3. Add the uniform aqueous phase mixture obtained in step S2 dropwise to the uniform oil phase mixture obtained in step S2, and stir at room temperature until a viscous reverse micelle is formed.
[0105] Each comparative example was prepared according to the following preparation method:
[0106] S1. Mix and stir the various raw materials in the aqueous phase until a homogeneous aqueous mixture is formed.
[0107] Performance testing
[0108] 1. In vitro transdermal assay:
[0109] The samples prepared in the aforementioned examples and comparative examples were subjected to transdermal experiments on isolated porcine skin using the vertical Franz diffusion cell method.
[0110] Piglet skin was fixed in the receiving chamber and the supply chamber. 0.5 g each of the reverse micelle transporter samples from each embodiment and the polypeptide aqueous solutions from Comparative Examples 1-3 were placed in the supply chamber. PBS buffer solution (pH 7.4) was used as the receiving solution, and the mixture was stirred and diffused at 32°C. After 24 hours, the skin was removed, washed, and minced. An appropriate amount of PBS buffer solution was added, and the mixture was shaken for half an hour. The supernatant was then collected for HPLC analysis to calculate the intradermal retention of specific components per unit area. The experimental results are shown in Table 4.
[0111] Table 4
[0112] The test results in Table 4 above show that:
[0113] Intradermal retention results showed that, compared with the polypeptide aqueous solutions of the various comparative examples, the reverse micelle transporters provided in each example all improved the intradermal retention of polypeptides to varying degrees. In particular, the combination of reverse micelle transporters with a ratio of 69.3% oil phase, 28.5% phospholipid, 1% antioxidant and 1.5% aqueous phase, wherein the aqueous phase includes 90% water and 10% polypeptide, can increase the intradermal retention of polypeptides by 71%-219%.
[0114] Viscosity was tested using the methods described above. Table 4 shows the viscosity results: compared to the polypeptide aqueous solutions of the comparative examples, the polypeptides transported by the reverse micelle carriers provided in each example exhibited significantly increased viscosity to varying degrees due to the formation of reverse micelle structures. Specifically, the viscosity of the reverse micelle carriers increased with increasing phospholipid content. However, the intradermal retention of the polypeptide did not increase with increasing viscosity; instead, it decreased. This is because excessively high viscosity of the reverse micelle carriers can hinder the release of the encapsulated polypeptides. Instead, an appropriate viscosity (25000 Pa·s-35000 Pa·s) provides both a reverse micelle structure and a certain degree of fluidity, thus better improving the intradermal retention of the polypeptide.
[0115] Applying this reverse micelle transporter to anti-aging cosmetics can greatly increase the intradermal retention of peptides, maximizing their efficacy and thus enhancing the anti-aging effects of the cosmetics.
[0116] 2. Microstructure characterization
[0117] The microstructure of the samples from Examples 2, 7, and 12 was observed using transmission electron microscopy, respectively.
[0118] 10 μl of each sample was dropped onto a copper grid and precipitated for 1 min. The floating liquid was then absorbed with filter paper. 10 μl of uranium acetate staining solution was dropped onto a copper grid and precipitated for 1 min. The floating liquid was then absorbed with filter paper. The samples were dried at room temperature for several minutes. Electron microscopy was performed at 80 kV-120 kV for detection and imaging, and the images were acquired and analyzed.
[0119] The transmission electron microscopy results are shown in Figures 1-3 of the instruction manual.
[0120] As can be seen from the transmission electron microscope images in Figures 1-3 of the instruction manual:
[0121] All samples in each embodiment exhibited a reverse micelle structure; and each reverse micelle structure was nanoscale and spherical. After loading conopodyne, snake venom-like peptide, and acetyl hexapeptide-8, the pore size of the reverse micelle structure was approximately 100nm-200nm. This nanoscale pore structure is more conducive to carrying peptides into the skin and increasing the amount of peptides retained in the skin. This is because the gap between the lipid bilayer of the normal stratum corneum is about 10nm-20nm. When the size of the reverse micelle carrier is about 100nm-200nm, its size is relatively moderate. On the one hand, it is larger than the gap between the intercellular lipid bilayer, and will not easily pass through normal lipid channels, thus avoiding excessively rapid passage through the stratum corneum and ineffective function; on the other hand, this size is not too large, allowing it to adhere to / penetrate the skin, increase skin hydration, relax the skin structure and change polarity, and promote peptide penetration through lipid exchange with intercellular lipids.
[0122] The above description is merely a preferred embodiment of this disclosure and is not intended to limit this disclosure. Various modifications and variations can be made to this disclosure by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this disclosure should be included within the scope of protection of this disclosure. Industrial applicability
[0123] This disclosure utilizes phospholipids to form reverse micelle structures, encapsulating water-soluble active ingredients and acting as carriers for them, thereby enhancing their stability. This reverse micelle structure can simultaneously transport peptides and increase their retention in the skin. The method provided in this disclosure is simple and easy to implement, possessing good industrial applicability.
Claims
1. A method for increasing the intradermal retention of polypeptides in cosmetics, characterized in that, include: An aqueous mixture was prepared by mixing the peptide with water. An oil-phase mixture was prepared by mixing phospholipids, oils, and antioxidants. The aqueous phase mixture is added dropwise to the oil phase mixture to form a viscous reverse micelle structure.
2. The method for increasing the intradermal retention of polypeptides in cosmetics according to claim 1, characterized in that, The method of preparing an aqueous mixture by mixing the polypeptide with water includes: In the aqueous mixture, the polypeptide is mixed with water at a mass percentage ratio of (0.01% to 70%):(30% to 99.99%).
3. The method for increasing the intradermal retention of polypeptides in cosmetics according to claim 1 or 2, characterized in that, The method of preparing an oil phase mixture by mixing phospholipids, oils, and antioxidants includes: The phospholipids, the oils and the antioxidants are mixed in a ratio of (20%–50%):(45%–78%):(1.0%–2.0%) by mass percentage.
4. The method for increasing the intradermal retention of polypeptides in cosmetics according to any one of claims 1-3, characterized in that, The step of adding the aqueous phase mixture dropwise to the oil phase mixture includes: The homogeneous aqueous phase mixture is added dropwise to the oil phase mixture while stirring.
5. The method for increasing the intradermal retention of polypeptides in cosmetics according to any one of claims 1-4, characterized in that, The step of adding the aqueous phase mixture dropwise to the oil phase mixture includes: In the aqueous phase mixture, 1%-3% of the aqueous phase mixture is added dropwise to 97%-99% of the oil phase mixture by mass, and the mixture is stirred.
6. The method for increasing the intradermal retention of polypeptides in cosmetics according to any one of claims 1-5, characterized in that, The oil includes at least one of isopropyl palmitate, isopropyl myristate, or isopropyl laurate. The antioxidants include: tocopherol acetate.
7. The method for increasing the intradermal retention of polypeptides in cosmetics according to any one of claims 1-6, characterized in that, The polypeptide includes at least one of conotoxin, snake venom-like peptide, or acetyl hexapeptide-8.
8. The method for increasing the intradermal retention of polypeptides in cosmetics according to any one of claims 1-7, characterized in that, The phospholipids include lecithin, and the purity of the lecithin is 90% to 100%.
9. An anti-aging cosmetic, characterized in that, The anti-aging cosmetics include polypeptide raw materials; The polypeptide raw material forms a viscous reverse micelle structure; Optionally, the pore size of the reverse micelle structure is 100nm-200nm; Optionally, the viscosity of the reverse micelle structure is 25000 Pa·s-35000 Pa·s.
10. The anti-aging cosmetic according to claim 9, characterized in that, The polypeptide raw material comprises, by weight percentage: 45%-78% oil; 20%-50% phospholipids; 1.0%-2.0% antioxidants; 1.0%-3.0% water; and 0.0001%-1.0% polypeptides; Optionally, the oil includes at least one of isopropyl palmitate, isopropyl myristate, or isopropyl laurate. Optionally, the antioxidant includes: tocopheryl acetate; Optionally, the polypeptide includes at least one of conotoxin, snake venom-like peptide, or acetyl hexapeptide-8; Optionally, the phospholipid includes lecithin, and the lecithin has a purity of 90% to 100%.